NCT00875264已完成1 期
An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
Cephalon0 个研究点目标入组 43 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 主要终点
- Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of CEP-11981, as defined in the Study Protocol.
研究概览
简要总结
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of CEP-11981 in patients with advanced, relapsed/refractory solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient:
- •has a histologically or cytologically confirmed solid tumor that has relapsed or is refractory. Additionally, the tumor must be considered unresponsive or poorly responsive to accepted treatment modalities.
- •has a life expectancy of at least 12 weeks.
- •has an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or
- •has normal neurologic examination findings. Patients having neurologic signs and symptoms indicative of brain metastases must undergo magnetic resonance imaging (MRI) to rule out brain metastases.
- •has fully recovered from any prior surgical procedure(s).
- •has fully recovered from reversible side effects of prior therapy for cancer including radiation therapy, chemotherapy, and immunotherapy.
- •is in appropriate health as determined by medical and psychiatric history, medical examination, electrocardiography (ECG), serum chemistry and hematology tests, and urinalysis.
- •if a woman of childbearing potential (not surgically sterile or who are not 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •if a man, not surgically sterile or who is capable of producing offspring, must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
- •is willing and able to comply with study restrictions and to return to the clinic for evaluations (including follow-up).
排除标准
- •The patient:
- •has any of the following hematologic values: absolute neutrophil count (ANC) less than 1500/mm3, platelet count less than 100000/mm3, hemoglobin less than 9 g/dL.
- •has any of the following hepatic function values: bilirubin greater than 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 times the ULN in the absence of known hepatic metastases, or ALT or AST greater than 3.0 times the ULN in the presence of known hepatic metastases.
- •has a serum creatinine value greater than 1.5 mg/dL.
- •has known cerebral metastases.
- •is currently on warfarin or heparin therapy.
- •has any pre-existing coagulopathy, recent hemoptysis, gross hematuria, or gastrointestinal bleeding, and a history of a clinically significant cardiovascular or cerebrovascular event within 6 months prior to study entry.
- •has uncontrolled hypertension defined as a blood pressure measurement greater than 150 mm Hg systolic or 90 mm Hg diastolic with medication.
- •is receiving any other antineoplastic treatment for solid tumors. (Continuing hormonal treatment is permitted.)
- •has received any investigational drug within the past 4 weeks.
- •has previously been enrolled in the study or received CEP-
- •has known hypersensitivity to gelatin or lactose monohydrate.
- •is a woman who is pregnant or lactating.
- •has taken a medication known to be a potent inducer of CYP1A2, CYP2C8, or CYP3A4 within 4 weeks prior to the first dose of study drug.
- •has taken a medication known to be a potent inhibitor of CYP1A2, CYP2C8, or CYP3A4 within 2 weeks prior to the first dose of study drug.
研究组 & 干预措施
1
Experimental
At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
干预措施: CEP-11981 (kinase inhibitor) (Drug)
结局指标
主要结局
Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of CEP-11981, as defined in the Study Protocol.
时间窗: At least one 6-week (42-day) cycle, which includes 28 days treatment during each cycle
次要结局
- Tumor response or progression using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.(At least one 6-week (42-day) cycle, which includes 28 days treatment during each cycle)
- Measurement of Pharmacokinetic parameters(Cycle 1 (42 days) and Day 1 of Cycle 2)
- Safety and tolerability of CEP-11981(At least one 6-week (42-day) cycle, which includes 28 days treatment during each cycle)
研究者
相似试验
已完成
1 期
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid TumorsSolid TumorsNCT01922752Teva Branded Pharmaceutical Products R&D, Inc.32
已完成
1 期
A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT01293630Sanofi18
撤回
1 期
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)Precursor Cell Lymphoblastic Leukemia-lymphomaNCT03888534Millennium Pharmaceuticals, Inc.
终止
1 期
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyMultiple MyelomaNCT01023880Cephalon62
已完成
1 期
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have SpreadNeoplasmsNCT04147247Boehringer Ingelheim21